Preliminary Safety and Clinical Observations From 4D pharma’s Phase I/II Study of MRx0518 in Combination With KEYTRUDA®
4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live Biotherapeutics, today announced preliminary safety and clinical observations from an ongoing Phase I/II clinical trial, in collaboration with MSD, a tradename […]